Comparative Pharmacology
Head-to-head clinical analysis: TRAMADOL versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAMADOL versus WESTADONE.
Tramadol vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Clinical Note
moderateTramadol + Torasemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide."
Clinical Note
moderateTramadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid."
Clinical Note
moderateTramadol + Furosemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide."
Clinical Note
moderateTramadol + Bumetanide
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide."